There are currently 53 active clinical trials seeking participants for Migraine research studies. The states with the highest number of trials for Migraine participants are Florida, California, Texas and New York.
MMA Embolization for Refractory Chronic Migraine
NCT06735833
Recruiting
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/17/2025
Locations: Mount Sinai, New York, New York +4 locations
Conditions: Migraine
Register for Updates
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/17/2025
Locations: Central Research Associates, Birmingham, Alabama +150 locations
Conditions: Migraine
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/17/2025
Locations: Central Research Associates, Birmingham, Alabama +134 locations
Conditions: Migraine
Register for Updates
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/16/2025
Locations: Paradigm Clinical Research Center Inc, San Diego, California +119 locations
Conditions: Migraine
Register for Updates
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06417775
Recruiting
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant i... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Central Research Associates /ID# 260161, Birmingham, Alabama +96 locations
Conditions: Migraine
Register for Updates
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/11/2025
Locations: Rehabilitation & Neurological Services /ID# 229969, Huntsville, Alabama +112 locations
Conditions: Migraine
Register for Updates
Evaluation of a Wearable Device for Acute Treatment of Migraines
NCT07015125
Recruiting
The goal of this clinical trial is to determine the efficacy of a new, improved neuromodulation device that can be worn on the head and neck to relieve migraine pain. To measure efficacy, investigators will compare how measured outcomes resulting from active stimulation with this device compare to those of sham treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Hinge Health, Inc., San Francisco, California
Conditions: Migraine, Migraine With or Without Aura, Migraine, Acute, Migraine Headache
Register for Updates
Family Study of Affective and Anxiety Spectrum Disorders
NCT00071786
Recruiting
This study will examine how depression, anxiety, and migraine run in families. It will help in defining the risk factors for physical, mental, and health problems-as well as define ways that those problems may be prevented and treated. A broad range of ages among family members will be included to evaluate the patterns of how these disorders are expressed throughout people's lives. Children of all ages will be included, and those ages 8 to 17 will be interviewed directly. Assessments will be c... Read More
Gender:
ALL
Ages:
Between 7 years and 120 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mood Disorders, Sleep Disorders, Migraine
Register for Updates
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056
Recruiting
This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during res... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/09/2025
Locations: Northern Arizona Healthcare, Flagstaff, Arizona +6 locations
Conditions: Migraine
Register for Updates
Cocoa Extract for Migraine Trial
NCT06808230
Recruiting
The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are: * Will we be able to enroll 114 participants during the recruitment period? * Will participants take study pills daily during the pill-taking period? Researchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Migraine
Register for Updates
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
NCT05198245
Recruiting
The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.
Gender:
FEMALE
Ages:
Between 16 years and 49 years
Trial Updated:
07/08/2025
Locations: Research Triangle Institute d/b/a RTI Health Solutions, Research Triangle Park, North Carolina
Conditions: Migraine
Register for Updates
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194
Recruiting
The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours In the 1st part of the study approximately half of the participants will r... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/08/2025
Locations: Nicklaus Children's Hospital, Miami, Florida +71 locations
Conditions: Migraine
Register for Updates